We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Evelo Biosciences Inc (EVLO) USD0.001

Sell:$0.0005 Buy:$0.0005 Change: No change
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$0.0005
Buy:$0.0005
Change: No change
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Deal now
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$0.0005
Buy:$0.0005
Change: No change
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.

Contact details

Address:
124 WASHINGTON STREET, SUITE 101
FOXBORO
02035
United States
Telephone:
+1 (617) 5770300
Website:
https://evelobio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EVLO
ISIN:
US2997342025
Market cap:
$9,470
Shares in issue:
18.93 million
Sector:
Biotechnology
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Craig Jalbert
    President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, Company Secretary, Director
  • Mark Bodmer
    Chief Scientific Officer, President of Research and Development
  • Daniel Char
    General Counsel, Secretary
  • Duncan McHale
    Chief Medical Officer
  • Mark Plinio
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.